David H. Johnson

发表

A Phase II study of all‐trans‐retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma

D. Ettinger, M. Jiroutek, M. Mabry, 1998, Cancer.

Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury

A. Doroszko, T. Hurst, G. Sawicki, 2010, Proteome Science.

Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells

D. Carbone, E. Harth, S. Novitskiy, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).

H. Choy, Y. Shyr, D. Johnson, 2000, International journal of radiation oncology, biology, physics.

Small cell carcinoma of the lung.

L. Einhorn, D. Johnson, F. Greco, 1986, Critical reviews in oncology/hematology.

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

M. Jiroutek, D. Cella, D. Fairclough, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.

S. Hoff, R. Adkins, David H. Johnson, 1993, The Annals of thoracic surgery.

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

R. Komaki, R. Livingston, W. Sause, 1999, The New England journal of medicine.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

S. Burdett, M. Parmar, R. Souhami, 2010 .

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

W. Curran, R. Livingston, W. Sause, 1995, Journal of the National Cancer Institute.

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

W. Curran, P. Kolesar, R. Livingston, 2001, Chest.

Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.

H. Choy, A. Chakravarthy, D. Johnson, 2000, Oncology.

Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.

M. Chen, R. Livingston, L. Einhorn, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

R. Livingston, L. Einhorn, P. Loehrer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

T Anderson, J. Glick, D. Karp, 1993, Journal of the National Cancer Institute.

A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

J P Pignon, M. Tattersall, R. Souhami, 1992, The New England journal of medicine.

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

M. Kris, W. Gradishar, G. Lyman, 1994, The New England journal of medicine.

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Yu Shyr, William J. Gradishar, G. Sledge, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.

D. Cella, S. Adak, J. Schiller, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

S. Adak, R. Livingston, M. Perry, 2000, The New England journal of medicine.

The role of radiation, with or without chemotherapy, in the management of NSCLC.

H. Choy, A. Chakravarthy, A. Chakravarthy, 1999, Oncology.

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.

D. Ettinger, D. Neuberg, A. Wolff, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.

A. Bartolucci, J. Crawford, D. Johnson, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

H. Choy, R. Arriagada, J. Pignon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

H. Choy, David H. Johnson, Y. Shyr, 2000, Clinical lung cancer.

R. Livingston, W. Sause, A. Turrisi, 2000, Cancer.

Atypical carcinoid of the lung. A distinct clinicopathologic entity.

D. Johnson, F. Greco, W. Macon, 1988, Chest.

Testicular function following combination chemotherapy with cis-platin, vinblastine, and bleomycin.

J. Hainsworth, D. Johnson, F. Greco, 1984, Medical and pediatric oncology.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

L. Stewart, S. Burdett, M. Parmar, 2010, The Lancet.

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.

Y. Shyr, C. Blanke, B. Murphy, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience.

D. Johnson, David H. Johnson, 2000, Chest.

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

V. Rusch, R. Livingston, D. Gandara, 2009, The Lancet.

Locally advanced, unresectable non-small cell lung cancer: new treatment strategies.

D. Johnson, David H. Johnson, 2000, Chest.

Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy

R. Wiesner, P. Kamath, Siddharth Singh, 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.